Disclosed is an immunoassay method for detecting an analyte such as an antigen or an antibody in an isolated sample suspected to contain the analyte by incubating the sample with a plurality of binding partners, one of which carries a detectable label, wherein a label-specific binding partner is added that does not carry a label but binds to the detectable label. The method is applicable for a large variety of analytes and has proven particularly useful for analyte antibodies of the IgG and IgM class present in samples due to infections by pathogens. Also disclosed is a reagent kit useful for the method comprising at least two analyte-specific binding partners one of which carries a detectable label and a label-specific binding partner that binds to said detectable label but itself does not carry a detectable label.

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.

Provided are methods for isolating subpopulations of stem cells. In some embodiments, the presently disclosed methods include selecting subsets of cells that are positive for CD34 or Sca-1, are further positive for one or more of FSHR, LHCGR, PRLR, AR, ESRα, ESRβ, and PGR; and are negative for each of CD45R/B220, Gr-1, TCRαβ, TCRγδ, CD11b, and Ter-119. In some embodiments, the subpopulations are further fractioning into CD45.sup.− and CD45.sup.+ fractions. Also provided are populations of stem cells isolated by the presently disclosed methods, compositions that include the presently disclosed subpopulations in pharmaceutically acceptable carriers, methods for expanding stem cells, methods for stimulating proliferation of MSCs, methods for treating subjects suffering from exposure to radiation, and methods for producing gametes in vitro.

Provided is a method for sorting a number of samples into an appropriate number of clusters according to their characteristics. Highly-correlated peaks are extracted from mass spectrum data obtained for the samples (S2). Using the extracted peaks, highly-correlated sample pairs are extracted (S3). While removing samples having low degrees of correlation, highly-correlated sample pairs are integrated to form core clusters (S4). Using singular peaks characterizing each core cluster, two or more core clusters are integrated to form clusters (S5-S7). These clusters include mixed clusters in which two or more clusters are mixed. Member determination formulae are created based on the singular peaks of each cluster (S8-S12). All samples, including those which have been excluded from the cluster determination process, are classified into clusters based on the member determination formulae (S14). The member determination formulae can also be used to assign a new sample to one of the cluster.

Provided is a method for sorting a number of samples into an appropriate number of clusters according to their characteristics. Highly-correlated peaks are extracted from mass spectrum data obtained for the samples (S2). Using the extracted peaks, highly-correlated sample pairs are extracted (S3). While removing samples having low degrees of correlation, highly-correlated sample pairs are integrated to form core clusters (S4). Using singular peaks characterizing each core cluster, two or more core clusters are integrated to form clusters (S5-S7). These clusters include mixed clusters in which two or more clusters are mixed. Member determination formulae are created based on the singular peaks of each cluster (S8-S12). All samples, including those which have been excluded from the cluster determination process, are classified into clusters based on the member determination formulae (S14). The member determination formulae can also be used to assign a new sample to one of the cluster.

Examples of determining and using physiological response estimates with glucose monitoring and insulin dosing systems and methods are disclosed. For example, one method includes receiving a selection of food items from a predefined catalog of food items as being part of a meal associated with a user profile, the catalog including nutritional information corresponding to food items in the catalog; determining nutritional information of the meal based on the nutritional information of each selected food item; receiving a notification from a user interface that a user associated with the user profile has started eating the meal; receiving successive indications of the user's glucose levels; computing a physiological response estimate associated with the user profile and the meal based on the successive indications of the user's glucose levels and the nutritional information of the meal.

An OH radical detection probe (102) includes an aromatic carboxylic acid, a polar aprotic organic solvent, and a polar protic organic solvent.

A method for recovering an acidic gas, includes: a step of bringing a gas to be treated that contains an acidic gas into gas-liquid into contact with an amine absorbing solution, allowing the amine absorbing solution to absorb the acidic gas, thereby removing the acidic gas from the gas to be treated; a step of allowing the amine absorbing solution that has absorbed the acidic gas to release the acidic gas, thereby regenerating the amine absorbing solution, and at the same time, recovering the released acidic gas; and an analysis step of calculating concentrations of iron ions and/or heavy metal ions in the amine absorbing solution.

The present disclosure describes a technology platform for creating and updating records of resources in a ledger. To create a record, a tenant organization may prepare a record to write to the ledger that may be flagged as temporary. Metadata may be added to the record, which flags the record as temporary. The metadata may comprise a unique code and an identification of a user that can approve the temporary record. The unique code and the identification may be sent, by the technology platform, to a device associated with one or more approving devices. Upon receiving the code and the identification of the transaction, the device may sign the unique code and invoke a routine based on the identification. The routine may fetch the temporary record. The device may compare the unique code to a code stored in the metadata of the temporary record. Upon valid verification of the unique code, the device may indicate authorization of the write. Based on the authorization, a proxy node associated with the technology platform may write a definitive record to the ledger based on the temporary record.